RxDoctor Payments Data

Neil Desai, MD

Radiation Oncology · Dallas, TXNPI 1366758237

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $18,496 of the $29,401 with a category attached, or 62.9%. Boston Scientific accounts for 71.1% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2021 at $9,250 and has fallen 88.4% since, to $1,071 in 2025. Among radiation oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,401in general payments, 2019–2025

Across 113 payments — averaging $260.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$21K
  • Telix Pharmaceuticals$3K
  • Novartis$2K
  • Pfizer$420
  • AstraZeneca$358
  • Johnson & Johnson$355
  • plus $2K from 19 others
$8,588,273in research payments, 2019–2025

Across 44 payments — averaging $195,188 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bayer$7.9M
  • Augmenix, Inc.$354K
  • Boston Scientific$223K
  • Pfizer$113K
  • Reflexion Medical, Inc.$33K

What the payments were for

  • Consulting fees$18,49663%
  • Speaking & faculty fees$3,25511%
  • Travel & lodging$1,6986%
  • Food & beverage$5,95220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,401 in reported general payments places this provider in the 95th percentile of 418 radiation oncology providers in Texas.

See all radiation oncology providers in Texas

Medicare billing

Part B allowed, 2024
$315,673
Medicare patients
271
Services billed
3,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix58$147,980
Estradiol (Once Weekly)Estradiol21$1,316
Tamsulosin Hcl83$1,243
Bicalutamide22$478
Venlafaxine Hcl ErVenlafaxine Hcl15$188

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →